To discuss currently available and emerging therapies in the treatment of sight-threatening non-infectious intermediate, posterior, and panuveitis.

    Session date: 
    Wednesday, March 7, 2018 - 7:00am to 8:00am
    Location: 
    Eye Institute
    925 N. 87th Street
    Lower Level Conference Room
    Milwaukee, WI 53226
    United States
    • 1.00 AMA PRA Category 1 Credit(s)™
      AMA PRA Category 1 Credit(s)™
    • 1.00 Hours of Participation
      Hours of Participation credit.

    Please login or register to take this course.
    Program Description: 

    Advanced in clinical and bench research in ophthalmology has produced multiple new treatment options for a variety of ocular diseases.  New technology, including the fast growing field of ocular imaging, is been used to further understand eye anatomy and pathology.  Progress in the field of ocular surgery has introduced new techniques and better outcomes.  The clinical and research environment is complex; issues related to ethics, quality improvement and new technology affect all eye care providers. The Eye Institute has, as one of its mission, the goal of being at the forefront of research, clinical care and education.  Our goal is to educate the academic and community eye care providers, residents, researchers and medical students on the best and newest clinical and surgical treatments, cutting edge research and important non-clinical topics available in the field.

    ACCME Accreditation Statement:

    The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    AMA Credit Designation Statement:

    The Medical College of Wisconsin designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    Hours of Participation for Allied Health Care Professionals
    The Medical College of Wisconsin designates this activity for up to 1.00 hours of participation for continuing education for allied health professionals.  

    Target audience: 
    Physicians
    Fellows
    Residents
    Community Physicians
    Allied Health Professionals
    Learning objectives: 
    1. To describe new treatment modalities in uveitis
    2. To discuss biologic drugs in the treatment of uveitis.
    3. To describe therapeutic agents and approaches currently in development.
    Faculty & credentials: 
    Presenter: Eric Suhler, MD, MPH
    Professor of Ophthalmology and Public Health
    Oregon Health & Science University;
    Chief of Ophthalmology, 
    Portland VA Health Care System
     

    All persons in control of content has no relevant financial relationships to disclose with the exception of: 

    Eric Suhler

    Santen, Mallinckrodt, Inotek

    Consultant

    Bristol Meyers Squibb, Genentech, EyeGate, Aldeyra, Clearside, pSivida, NEI/NIH

    Researcher/ Site PI

    Gilead

    Consultant (clinical trial steering committee) Researcher (local Site PI)

    Abbvie

    Consultant (including clinical trial steering committee, VISUAL studies, and global lead investigator, VISUAL III study); Researcher, (local site PI) and Speakers Bureau

    In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved

    CME Coordinator Contact Information

    Name: 
    Mary Schafer
    Phone number: 
    +1 (414) 955-7840